Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 2.17
REGN's Cash-to-Debt is ranked lower than
71% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. REGN: 2.17 )
Ranked among companies with meaningful Cash-to-Debt only.
REGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.67  Med: 2.07 Max: No Debt
Current: 2.17
Equity-to-Asset 0.64
REGN's Equity-to-Asset is ranked lower than
51% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. REGN: 0.64 )
Ranked among companies with meaningful Equity-to-Asset only.
REGN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.27  Med: 0.56 Max: 0.87
Current: 0.64
0.27
0.87
Interest Coverage 184.95
REGN's Interest Coverage is ranked lower than
69% of the 490 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. REGN: 184.95 )
Ranked among companies with meaningful Interest Coverage only.
REGN' s Interest Coverage Range Over the Past 10 Years
Min: 10.1  Med: 22.05 Max: 184.95
Current: 184.95
10.1
184.95
Piotroski F-Score: 5
Altman Z-Score: 11.69
Beneish M-Score: -2.77
WACC vs ROIC
14.94%
25.91%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 27.38
REGN's Operating Margin % is ranked higher than
90% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. REGN: 27.38 )
Ranked among companies with meaningful Operating Margin % only.
REGN' s Operating Margin % Range Over the Past 10 Years
Min: -91.55  Med: 3.92 Max: 35.3
Current: 27.38
-91.55
35.3
Net Margin % 18.10
REGN's Net Margin % is ranked higher than
88% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. REGN: 18.10 )
Ranked among companies with meaningful Net Margin % only.
REGN' s Net Margin % Range Over the Past 10 Years
Min: -84.46  Med: -2.95 Max: 54.43
Current: 18.1
-84.46
54.43
ROE % 21.53
REGN's ROE % is ranked higher than
93% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. REGN: 21.53 )
Ranked among companies with meaningful ROE % only.
REGN' s ROE % Range Over the Past 10 Years
Min: -43.76  Med: -0.78 Max: 86.68
Current: 21.53
-43.76
86.68
ROA % 13.96
REGN's ROA % is ranked higher than
93% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. REGN: 13.96 )
Ranked among companies with meaningful ROA % only.
REGN' s ROA % Range Over the Past 10 Years
Min: -18.38  Med: 0.35 Max: 44.08
Current: 13.96
-18.38
44.08
ROC (Joel Greenblatt) % 45.22
REGN's ROC (Joel Greenblatt) % is ranked higher than
91% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. REGN: 45.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
REGN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -173.81  Med: 7.5 Max: 61.97
Current: 45.22
-173.81
61.97
3-Year Revenue Growth Rate 30.20
REGN's 3-Year Revenue Growth Rate is ranked higher than
78% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. REGN: 30.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
REGN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -25  Med: 33.3 Max: 81.1
Current: 30.2
-25
81.1
3-Year EBITDA Growth Rate 20.70
REGN's 3-Year EBITDA Growth Rate is ranked higher than
72% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. REGN: 20.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
REGN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -24.4  Med: 29.85 Max: 83.5
Current: 20.7
-24.4
83.5
3-Year EPS without NRI Growth Rate 27.40
REGN's 3-Year EPS without NRI Growth Rate is ranked higher than
81% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. REGN: 27.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
REGN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -21.8  Med: 4.95 Max: 86.3
Current: 27.4
-21.8
86.3
GuruFocus has detected 3 Warning Signs with Regeneron Pharmaceuticals Inc $REGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» REGN's 10-Y Financials

Financials (Next Earnings Date: 2017-05-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

REGN Guru Trades in Q1 2016

Ray Dalio 900 sh (New)
Steven Cohen 109,700 sh (New)
Jim Simons 216,962 sh (+102.27%)
Vanguard Health Care Fund 3,169,490 sh (+38.98%)
Eaton Vance Worldwide Health Sciences Fund 137,000 sh (+23.42%)
Paul Tudor Jones Sold Out
Pioneer Investments Sold Out
Ken Fisher 613 sh (-0.33%)
Mario Gabelli 1,343 sh (-2.54%)
Frank Sands 3,387,921 sh (-8.40%)
Ron Baron 5,011 sh (-32.86%)
Joel Greenblatt 2,525 sh (-39.26%)
» More
Q2 2016

REGN Guru Trades in Q2 2016

Paul Tudor Jones 2,956 sh (New)
Joel Greenblatt 30,151 sh (+1094.10%)
Vanguard Health Care Fund 3,279,190 sh (+3.46%)
Ken Fisher 613 sh (unchged)
Ray Dalio Sold Out
Steven Cohen Sold Out
Ron Baron 4,987 sh (-0.48%)
Mario Gabelli 1,329 sh (-1.04%)
Jim Simons 210,762 sh (-2.86%)
Frank Sands 2,659,741 sh (-21.49%)
Eaton Vance Worldwide Health Sciences Fund 108,200 sh (-21.02%)
» More
Q3 2016

REGN Guru Trades in Q3 2016

George Soros 1,381 sh (New)
Paul Tudor Jones 4,608 sh (+55.89%)
Ken Fisher 620 sh (+1.14%)
Vanguard Health Care Fund 3,279,190 sh (unchged)
Jim Simons Sold Out
Ron Baron 4,924 sh (-1.26%)
Frank Sands 2,497,378 sh (-6.10%)
Joel Greenblatt 24,745 sh (-17.93%)
Mario Gabelli 529 sh (-60.20%)
Eaton Vance Worldwide Health Sciences Fund 60,662 sh (-43.94%)
» More
Q4 2016

REGN Guru Trades in Q4 2016

Jim Simons 250,560 sh (New)
Manning & Napier Advisors, Inc 440,316 sh (New)
Ken Fisher 715 sh (+15.32%)
Vanguard Health Care Fund 3,309,690 sh (+0.93%)
Ron Baron 4,969 sh (+0.91%)
Eaton Vance Worldwide Health Sciences Fund 60,662 sh (unchged)
George Soros Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli Sold Out
Frank Sands 2,302,802 sh (-7.79%)
Joel Greenblatt 12,096 sh (-51.12%)
» More
» Details

Insider Trades

Latest Guru Trades with REGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BMRN, NAS:BCRX, NAS:ANIP, NAS:BSTC, AMEX:BTX, NAS:CASC, NAS:BDSI » details
Traded in other countries:RGO.Germany, REGN.Mexico, REGN.Switzerland, 0R2M.UK,
Regeneron Pharmaceuticals Inc is a fully integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has four marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; and Arcalyst in CAPS. Regeneron is also developing monoclonal antibodies with Sanofi in rheumatoid arthritis, atopic dermatitis, asthma, and cancer.

Guru Investment Theses on Regeneron Pharmaceuticals Inc

Baron Funds Comments on Regeneron Pharmaceuticals - May 23, 2016

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) fell in the first quarter as a result of the significant sell-off in the biotech/pharma space and a miss on the top and bottom lines versus the expected fourth quarter results. 2016 guidance for Eylea (its lead ophthalmology asset) was sharply down from 2015. Launch of its new cardiovascular drug, Praluent, has been slow, and it lost a court case involving the drug. We have trimmed our position but decided that Regeneron deserved benefit of the doubt. Given Sanofi’s 22% ownership and its reliance on company for R&D productivity, we believe Regeneron enjoys a privileged position in the biotech universe.



From Baron Fifth Avenue Growth Fund first quarter commentary 2016.



Check out Ron Baron latest stock trades

Top Ranked Articles about Regeneron Pharmaceuticals Inc

Manning & Napier’s Top 3 New Holdings Firm invested in wide array of industries in the 4th quarter
Manning & Napier Advisors Inc. acquired 35 new holdings during the final quarter of 2016. The firm’s top three new holdings are Bristol-Myers Squibb Co. (NYSE:BMY), Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Campbell Soup Co. (NYSE:CPB). Read more...
Baron Funds Comments on Regeneron Pharmaceuticals Guru stock highlight
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) fell in the first quarter as a result of the significant sell-off in the biotech/pharma space and a miss on the top and bottom lines versus the expected fourth quarter results. 2016 guidance for Eylea (its lead ophthalmology asset) was sharply down from 2015. Launch of its new cardiovascular drug, Praluent, has been slow, and it lost a court case involving the drug. We have trimmed our position but decided that Regeneron deserved benefit of the doubt. Given Sanofi’s 22% ownership and its reliance on company for R&D productivity, we believe Regeneron enjoys a privileged position in the biotech universe. Read more...
Vanguard Boosts Stake in Incyte in 1st Quarter Guru sells holdings in CVS Health, Edwards Lifesciences, Monsanto
Vanguard Health Care Fund continued a streak of double-digit returns in 2015 with returns of 12.65%. That is below the fund’s returns levels of 2014 (28.52%) and 2013 (43.19%), but it is still in double digits, which was a considerable achievement in 2015’s challenging investing environment. Read more...

Ratios

vs
industry
vs
history
PE Ratio 50.48
REGN's PE Ratio is ranked lower than
71% of the 285 Companies
in the Global Biotechnology industry.

( Industry Median: 28.64 vs. REGN: 50.48 )
Ranked among companies with meaningful PE Ratio only.
REGN' s PE Ratio Range Over the Past 10 Years
Min: 22.84  Med: 74.67 Max: 169.6
Current: 50.48
22.84
169.6
Forward PE Ratio 27.70
REGN's Forward PE Ratio is ranked lower than
64% of the 84 Companies
in the Global Biotechnology industry.

( Industry Median: 20.12 vs. REGN: 27.70 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 50.48
REGN's PE Ratio without NRI is ranked lower than
73% of the 259 Companies
in the Global Biotechnology industry.

( Industry Median: 28.10 vs. REGN: 50.48 )
Ranked among companies with meaningful PE Ratio without NRI only.
REGN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 22.84  Med: 74.67 Max: 169.6
Current: 50.48
22.84
169.6
Price-to-Owner-Earnings 80.10
REGN's Price-to-Owner-Earnings is ranked lower than
74% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 31.38 vs. REGN: 80.10 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
REGN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 49.67  Med: 103.38 Max: 1511.41
Current: 80.1
49.67
1511.41
PB Ratio 9.14
REGN's PB Ratio is ranked lower than
81% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. REGN: 9.14 )
Ranked among companies with meaningful PB Ratio only.
REGN' s PB Ratio Range Over the Past 10 Years
Min: 2.47  Med: 9.65 Max: 26.41
Current: 9.14
2.47
26.41
PS Ratio 9.14
REGN's PS Ratio is ranked higher than
60% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. REGN: 9.14 )
Ranked among companies with meaningful PS Ratio only.
REGN' s PS Ratio Range Over the Past 10 Years
Min: 3.69  Med: 12.3 Max: 27.67
Current: 9.14
3.69
27.67
Price-to-Free-Cash-Flow 46.51
REGN's Price-to-Free-Cash-Flow is ranked lower than
68% of the 173 Companies
in the Global Biotechnology industry.

( Industry Median: 24.12 vs. REGN: 46.51 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
REGN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 36.13  Med: 99.23 Max: 7496
Current: 46.51
36.13
7496
Price-to-Operating-Cash-Flow 30.29
REGN's Price-to-Operating-Cash-Flow is ranked lower than
65% of the 232 Companies
in the Global Biotechnology industry.

( Industry Median: 20.83 vs. REGN: 30.29 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
REGN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 21.69  Med: 51.45 Max: 316.18
Current: 30.29
21.69
316.18
EV-to-EBIT 30.02
REGN's EV-to-EBIT is ranked lower than
67% of the 320 Companies
in the Global Biotechnology industry.

( Industry Median: 21.73 vs. REGN: 30.02 )
Ranked among companies with meaningful EV-to-EBIT only.
REGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -108.7  Med: 4 Max: 1948.5
Current: 30.02
-108.7
1948.5
EV-to-EBITDA 27.84
REGN's EV-to-EBITDA is ranked lower than
66% of the 355 Companies
in the Global Biotechnology industry.

( Industry Median: 16.79 vs. REGN: 27.84 )
Ranked among companies with meaningful EV-to-EBITDA only.
REGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -141.9  Med: 3.6 Max: 387.4
Current: 27.84
-141.9
387.4
Shiller PE Ratio 198.33
REGN's Shiller PE Ratio is ranked lower than
93% of the 54 Companies
in the Global Biotechnology industry.

( Industry Median: 52.28 vs. REGN: 198.33 )
Ranked among companies with meaningful Shiller PE Ratio only.
REGN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 179.53  Med: 583.73 Max: 4161.1
Current: 198.33
179.53
4161.1
Current Ratio 2.56
REGN's Current Ratio is ranked lower than
66% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. REGN: 2.56 )
Ranked among companies with meaningful Current Ratio only.
REGN' s Current Ratio Range Over the Past 10 Years
Min: 2.56  Med: 6.12 Max: 17.9
Current: 2.56
2.56
17.9
Quick Ratio 2.24
REGN's Quick Ratio is ranked lower than
66% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. REGN: 2.24 )
Ranked among companies with meaningful Quick Ratio only.
REGN' s Quick Ratio Range Over the Past 10 Years
Min: 2.24  Med: 6.01 Max: 17.72
Current: 2.24
2.24
17.72
Days Inventory 390.44
REGN's Days Inventory is ranked lower than
90% of the 384 Companies
in the Global Biotechnology industry.

( Industry Median: 132.21 vs. REGN: 390.44 )
Ranked among companies with meaningful Days Inventory only.
REGN' s Days Inventory Range Over the Past 10 Years
Min: 97.79  Med: 170.76 Max: 780.78
Current: 390.44
97.79
780.78
Days Sales Outstanding 121.03
REGN's Days Sales Outstanding is ranked lower than
79% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. REGN: 121.03 )
Ranked among companies with meaningful Days Sales Outstanding only.
REGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 23.13  Med: 93.08 Max: 157.07
Current: 121.03
23.13
157.07
Days Payable 164.40
REGN's Days Payable is ranked higher than
78% of the 353 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. REGN: 164.40 )
Ranked among companies with meaningful Days Payable only.
REGN' s Days Payable Range Over the Past 10 Years
Min: 131.02  Med: 172.72 Max: 2718.58
Current: 164.4
131.02
2718.58

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.10
REGN's 3-Year Average Share Buyback Ratio is ranked higher than
83% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. REGN: -2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
REGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.7  Med: -6.3 Max: -2.1
Current: -2.1
-14.7
-2.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 61.98
REGN's Price-to-Net-Current-Asset-Value is ranked lower than
97% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 5.79 vs. REGN: 61.98 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
REGN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.4  Med: 12.95 Max: 61.98
Current: 61.98
3.4
61.98
Price-to-Tangible-Book 9.14
REGN's Price-to-Tangible-Book is ranked lower than
76% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. REGN: 9.14 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
REGN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.74  Med: 5.79 Max: 16.48
Current: 9.14
1.74
16.48
Price-to-Intrinsic-Value-Projected-FCF 5.04
REGN's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
60% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 3.58 vs. REGN: 5.04 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
REGN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 4.82  Med: 13.29 Max: 27.75
Current: 5.04
4.82
27.75
Price-to-Median-PS-Value 0.74
REGN's Price-to-Median-PS-Value is ranked higher than
72% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. REGN: 0.74 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
REGN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.25  Med: 1.04 Max: 4.3
Current: 0.74
0.25
4.3
Price-to-Graham-Number 4.50
REGN's Price-to-Graham-Number is ranked lower than
74% of the 197 Companies
in the Global Biotechnology industry.

( Industry Median: 2.57 vs. REGN: 4.50 )
Ranked among companies with meaningful Price-to-Graham-Number only.
REGN' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.25  Med: 5.56 Max: 10.04
Current: 4.5
1.25
10.04
Earnings Yield (Greenblatt) % 3.33
REGN's Earnings Yield (Greenblatt) % is ranked higher than
83% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. REGN: 3.33 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
REGN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 2.3 Max: 24.9
Current: 3.33
0.1
24.9

More Statistics

Revenue (TTM) (Mil) $4,860
EPS (TTM) $ 7.60
Beta1.69
Short Percentage of Float2.95%
52-Week Range $325.35 - 452.96
Shares Outstanding (Mil)106.08

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 5,444 5,936 6,719
EPS ($) 12.94 14.74 18.21
EPS without NRI ($) 12.94 14.74 18.21
EPS Growth Rate
(Future 3Y To 5Y Estimate)
14.97%
Dividends per Share ($)
» More Articles for REGN

Headlines

Articles On GuruFocus.com
Manning & Napier’s Top 3 New Holdings Jan 26 2017 
A Green Light on Bayer Jan 19 2017 
Largest Insider Trades of the Week Jan 16 2017 
Take a Look at Sanofi Oct 05 2016 
3 of Frank Sands' Top 5 Transactions in 2nd Quarter Were Reductions Aug 14 2016 
Edward Owens Top 2nd Quarter Investments Aug 03 2016 
Frank Sands Sells Visa, Baidu, Alibaba May 24 2016 
Baron Funds Comments on Regeneron Pharmaceuticals May 23 2016 
Market-Beating Vanguard Health Care Fund Adds Shares to 5 Positions May 03 2016 
Vanguard Boosts Stake in Incyte in 1st Quarter May 02 2016 

More From Other Websites
Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : REGN-US :... Mar 24 2017
Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved Mar 24 2017
Regeneron, Sanofi Look To Crush Amgen, And Rivals Say They Can Mar 23 2017
Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency Mar 23 2017
[$$] DNA decoding initiative to involve 500,000 middle-aged Britons Mar 22 2017
GSK and Regeneron to mine gene data from 500,000 Britons Mar 22 2017
GSK and Regeneron to mine gene data from 500,000 Britons Mar 22 2017
U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World's Most Detailed... Mar 22 2017
Sanofi-Genzyme files preemptive legal strike to protect eczema drug Mar 21 2017
Sanofi, Regeneron sue Amgen to protect eczema drug from patent claims Mar 21 2017
Amgen (AMGN): Repatha Outcomes Data Disappoint, Shares Drop Mar 20 2017
European Stocks Drift Lower; Deutsche Bank Falls on Rights Issue Details Mar 20 2017
European Stocks Set For Mixed Open: Dollar Slumps in Quiet Asia Trade Mar 20 2017
Amgen’s Repatha Study Shows Reduced Risk of Heart Attack, Stroke Mar 17 2017
Amgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke Mar 17 2017
The Biggest Loser: Amgen Drops 6.4% Mar 17 2017
Esperion's Dive On Amgen Heart Study 'Counterintuitive' On Pricing Mar 17 2017
CVS Health says Amgen data may increase eligible patients by millions Mar 17 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)